3 Stocks That Absolutely Crushed the Market on Friday -- Here's Why athenahealth inc, Puma Biotechnology Inc, and Cytokinetics, Inc Left Investors Smiling

These health-care stocks have winning written all over them. Here's why athenahealth inc, Puma Biotechnology Inc, and Cytokinetics, Inc. popped on the market today.

Feb 7, 2014 at 7:05PM

Several companies benefited from an overall biotech bounce-back today, but Athenahealth (NASDAQ:ATHN), Puma Biotechnology (NYSE:PBYI) and Cytokinetics (NASDAQ:CYTK) were three health-care stocks that saw big pops on specific company news, which made them today's winners in the space.

Puma Biotechnology got a 15% boost after the European Patent Office ruled in the company's favor. The matter involved Boehringer Ingleheim challenging the validity of one of the company's drug patents, a vital patent for the company, as Puma only has one drug. The drug is in nine different trials with other drugs to treat breast and lung cancer, and the company is definitely one to watch.

Cytokinetics is up 30% today, thanks to some tremendous fourth-quarter results. Revenue increased elevenfold year over year, and the company had a colossal earnings beat, coming in at $0.21 per share in the black, as compared to analysts' predictions of $0.08 per share in the red. While the company is working on three drugs, the most-hyped is its heart failure drug in collaboration with Amgen. in the video, Motley Fool health-care analyst David Williamson suggests that investors wait to get more data here before jumping in.

Athenahealth also popped today, up 25% after announcing its fourth-quarter results. Revenue grew substantially, to $171 million, which slightly beat estimates, but the company annihilated estimates on the bottom line, coming in at $0.57 per share vs. the $0.44 per share consensus. David sees the company as showing good network growth, and executing its expansion plans smoothly and solidly.

So what's the best way for investors to play the biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends Athenahealth. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information